PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 45: Articles 22001-22500 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. More about natural family planning.
  2. Mortality in women of reproductive age due to diseases of the circulatory system caused by the use of oral contraceptives in Yugoslavia. [Mortalitet zena generativnog perioda od bolesti cirkulatornog sistema obziorm na koriscenje oralne kontracepcije u Jugoslaviji.]
  3. Multilevel effects of socioeconomic development and family planning programs on children ever born [tables]
  4. Multilevel effects of socioeconomic development and family planning programs on children ever born.
  5. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate: final report.
  6. Myocardial infarction, oral contraception, cigarette smoking, and coronary artery spasm in young women.
  7. The National Conference of Propaganda Work on Family Planning held Beijing.
  8. National family planning program of the Dominican Republic.
  9. Natural family planning [letter]
  10. Natural family planning is the way to go.
  11. Natural family planning methods including breast feeding. Current status and problems.
  12. Natural Family Planning Programme in India and the laity's responsibility.
  13. The Natural Family Planning Programme of Changanacherry family apostolate.
  14. Natural family planning works in a Bukidnon town.
  15. Natural Family Planning.
  16. Natural family planning. [Planificacion familiar natural.]
  17. Natural family planning: a birth control alternative.
  18. Natural family planning: an overview.
  19. Natural family planning: readers comment [letter]
  20. Natural family planning: yesterday, today, and tomorrow.
  21. Natural methods of contraception.
  22. Need and use of research in the voluntary surgical contraception experience in the Dominican Republic.
  23. The need to know: recalled adolescent sources of sexual and contraceptive information and sexual behavior.
  24. Needs of youth in family planning: the problem in Latin America. A equivocal policy: putting the cart before the horse. [Necesidades de los jovenes en planificacion familiar: el problema en America Latina. Una politica equivocada: poner la carreta delante de los bueyes.]
  25. Nepal contraceptive prevalence survey report 1981.
  26. Nepal Contraceptive Retail Sales (CRS) Company Pvt. Ltd. at a glance.
  27. The Nepal CRS Project: marketing family planning the the shops of Nepal. Report 1976-1983.
  28. A new approach to an age-old problem: upgrading the skills of family planning practitioners.
  29. New approaches to female contraception: LHRH.
  30. New approaches to male fertility regulation: LHRH analogs, steroidal contraception, and inhibin.
  31. A new contraceptive sponge and its potential in prevention of sexually transmitted diseases.
  32. New contraceptives for men. What are the prospects? [editorial]
  33. New contraceptives tested for women and men.
  34. New roads to contraception.
  35. New techniques in contraception: gossypol, vaccines and GnRH analogues.
  36. A new ultra-low-dose combination oral contraceptive.
  37. The next twenty years with contraceptive method. [Los proximos 20 anos con metodos contraceptivos.]
  38. The Ninth Asian Parasite Control/Family Planning Conference: proceedings/October 18-23, 1982, Seoul, Republic of Korea.
  39. Non-contraceptive benefits of vaginal spermicides.
  40. Non-hormonal methods of contraception in diabetic women: reliability, risks, precautions, follow-up. [Methodes non hormonales de contraception chez les femmes diabetiques: fiabilite, risques, precautions, surveillance.]
  41. Norethisterone enanthate injectable contraceptive.
  42. Normative and psychic costs of contraception.
  43. Norplant contraceptive implants: instructions for clinicians. Rev. ed.
  44. Norplant contraceptive subdermal implants.
  45. NORPLANT subdermal implants approved by Finland: worldwide effort to introduce new contraceptive begins [news release]
  46. A note on desired family size and contraceptive use in rural Egypt.
  47. The nurse-midwife in a contraceptive program for adolescents.
  48. Nutritional consequences of oral contraceptives.
  49. Occlusive arteriopathy of the circle of Willis with outlined "Moya-Moya" network in a woman with migraine under oral contraception. Regressive course (author's transl) [Arteriopathie occlusive du polygone de Willis avec ebauche de reseau "Moya-Moya" survenue chez une jeune femme migraineuse sous medication contraceptive. Evolution regressive.]
  50. On the eve of birth control. I. [U progu regulacji urodzen (I)]
  51. On the eve of birth control. II. [U progu regulacji urodzen (II)]
  52. On the use of voluntary female surgical contraception in Brazil.
  53. A one-sided view of natural family planning.
  54. Only a third of all women use a contraceptive method correctly. [Endast en tredjedel av kvinnorna anvander nagon preventivmetod pa ett korrekt satt.]
  55. Open up a new prospect for family planning.
  56. Operational responses to the World Population Plan of Action in programmes of the United Nations Fund for Population Activities in the areas of fertility, family and family planning.
  57. Operations research in family planning and primary health care: report on a workshop.
  58. Operations research project summary. Operational research on social marketing of contraceptives Sri Lanka.
  59. Operations research to support family planning and primary health care in Haiti.
  60. Oral contraception and cardiovascular complications. [Anticoncepcionais orais e complicacoes cardiovasculares.]
  61. Oral contraception and cerebral thrombosis in a Jamaican.
  62. Oral contraception and coronary heart disease.
  63. Oral contraception with a new biphasic preparation. [Orale Kontrazeption mit neuem Zweiphasenpraparat.]
  64. Oral contraception with a nonalkylated estrogen component. Effects on lipid metabolism.
  65. Oral contraception [response to question] [letter]
  66. Oral contraception. [La contraception orale.]
  67. Oral contraception: selection and management.
  68. Oral contraception: update. [Les contraceptifs oraux: mise a jour.]
  69. Oral contraceptive hazards--reappraisal.
  70. Oral contraceptive steroids impair the elimination of theophylline.
  71. Oral Contraceptive use and fibrocystic breast disease with special reference to its histopathology.
  72. Oral contraceptives and the risk of cardiovascular disease.
  73. Oral contraceptives and von Willebrand's disease [letter]
  74. Oral contraceptives containing estrogen plus progestogen.
  75. Oral contraceptives, carbohydrate metabolism and diabetes mellitus. [Contraceptifs oraux, metabolisme hydorcarbone et diabete sucre.]
  76. Oral contraceptives, methionine and endothelial lesion.
  77. Oral contraceptives.
  78. Oral contraceptives: contraindications and management of side effects.
  79. Oral contraceptives: recent safety studies (author's transl) [Contraceptifs oraux: recentes etudes de tolerance.]
  80. Oral contraceptives: the good news [editorial]
  81. Poly net contraceptive system.
  82. Poly(lactic acid) and poly(lactic acid-co-glycolic acid) contraceptive delivery systems.
  83. Population and family planning in Bangladesh: a survey of the research.
  84. Population policy as a rationale for voluntary surgical contraception services.
  85. Post coital contraception [letter]
  86. The post partum voluntary surgical contraception program in Indonesia.
  87. Postcoital birth control: a significant addition to family planning services.
  88. Postcoital contraception [excerpt from letter]
  89. Postcoital contraception or abortion? [letter]
  90. Postcoital contraception or abortion] [letter.
  91. Postcoital contraception [letter]
  92. Postcoital contraception--notes for doctors.
  93. Postcoital contraception.
  94. Postcoital contraception.
  95. Postcoital contraception. [Postkoital kontraception.]
  96. Postcoital contraception: methods, services and prospects.
  97. The postcoital pill and intrauterine device: contraceptive or abortifacient?
  98. Postpartum amenorrhea in selected developing countries: estimates from contraceptive prevalence surveys.
  99. Practice and problems of postcoital contraception in general practice.
  100. A practice audit of oral contraceptive users.
  101. Practices in pregnancy and family planning of women in slum and the government housing project of the Din-Daeng community, Bangkok, 1981.
  102. Predicting contraceptive behavior from attitudes: a comparison of within- versus across-subjects procedures.
  103. Pregnancy-associated alpha-glycoprotein, oral contraceptives, and rheumatoid arthritis [letter]
  104. Preliminary estimates of the population "at risk" of pregnancy and of those using contraception. Findings from Cycle III of the National Survey of Family Growth.
  105. Prescribing of oral contraceptives in Oxfordshire.
  106. Present status of voluntary surgical contraception in Sub-Saharan Africa.
  107. The present task of family planning as suggested by the findings of the National Sample Survey of Fertility.
  108. Prevalence of anemia in clients of a family planning clinic in Merida. [Prevalencia de anemia en usuarias de una clinica de planificacion familiar de Merida.]
  109. Preventing contraceptive spoilage: guidelines for family planning program officers and administrators.
  110. Pricing considerations in contraceptive social marketing programs.
  111. Prior contraceptive attempts among pregnant black adolescents.
  112. The private physician and family planning. [El medico privado y la planificacion familiar.]
  113. Problem areas, part 11: contraception and pregnancy.
  114. Proceedings of the Fifteenth Annual Conference, Association for Population/Family Planning Libraries and Information Centers--International, Holiday Hills Conference Center, Pawling, New York, May 3-5, 1982. The future of APLIC in population information services: options and directions.
  115. Proceedings of the International Conference on Population and Family Planning, 6-8 January 1983, Taipei, Taiwan, Republic of China.
  116. PROFAM expands Mexican family planning clinics.
  117. Professor Wu Jiepeng, prominent urologist, says men should assume more obligations in birth control; ligation surgery is simpler for men than for women.
  118. The PROGEB-simulation model for determining family planning targets. [Die PROGEB-simulasiemodel vir die bepaling van gesinsbeplanningsdoelwitte.]
  119. Progestins in contraception--present and future.
  120. Program performance: the assessment of Asian family planning programs.
  121. Program performance: the assessment of Asian family planning programs.
  122. Programmatic considerations in meeting the demand for voluntary surgical contraception in the 1980's.
  123. Programs in implementing family planning programme in Karnataka: a study of medical, para-medical personnel and local leaders.
  124. Progress report on WHO Sponsored Service Research Project in Family Planning and Family Health: 80030--20 August 1982-28 February 1983.
  125. Project handbook: a practical guide for pharmacists on running Stage III of the FPA / Pharmaceutical Society joint project: "Family Planning and the Pharmacist".
  126. Project progress report I: Integrated Family Planning, Nutrition and Parasite Control Project of Bangladesh.
  127. Recent advances in barrier methods of contraception.
  128. Recent research on the availability of family planning methods in developing countries.
  129. Reducing fertility through family planning in Nepal: a cost-benefit evaluation.
  130. Refresher training of clinic workers for family planning in Egypt.
  131. Regression analysis of changes in blood pressure with oral contraceptive use.
  132. Relations between the use of health services and family planning.
  133. The relationship between psychological characteristics and contraceptive behaviors among university women.
  134. The relationship between the level of moral development and birth control usage and pregnancy among teenage girls.
  135. The relationship of cognitive development and decision making to the initiation of effective contraception by adolescent women.
  136. Religious identity and attitudes toward contraceptives among university students in Nigeria.
  137. Relocation and population planning: a study of the implications of public housing and family planning in Singapore.
  138. The renin-angiotensin system and total body sodium and potassium in hypertensive women taking oestrogen-progestagen oral contraceptives.
  139. The reorganization of Karnataka State District Family Planning Department, India.
  140. Reply to Agius letter on natural family planning] [letter.
  141. Reply to Dr. Andrade [concerning oral contraceptives and postoperative venous thrombosis] [letter]
  142. Reply to letter by Back and Orme [concerning oral contraceptives and ascorbic acid metabolism] [letter]
  143. Report of the basic marketing study of the International Contraceptive Marketing Project, conducted in El Salvador.
  144. Report of the regional meeting on social and cultural factors affecting the acceptance, continuation and discontinuation of family planning practice.
  145. Report of the Working Group on the Promotion of Family Planning as a Basic Human Right to the Member's Assembly and the Central Council of the International Planned Parenthood Federation.
  146. A report on attitudes towards family planning and family size in Botswana.
  147. Report on Development Associates' seminar on resource development for private non-profit family planning providers in Latin America, October 16-20, 1983 San Andres, Colombia.
  148. A report on Planned Parenthood of Central Ohio's campaign to reach teenage boys.
  149. Report on the evaluation of the regional advisory team for family planning (SEARO)
  150. Report on the evaluation of UNFPA assistance to population education projects executed by the ILO in Bangladesh: BGD/74/PO4--pilot project for family planning motivation and services in industry and plantations; and BGD/80/PO3--population and family welfare motivation and services in industry (November 1982)
  151. Report on the opinion survey of political, professional, communication and top-level leaders on population and family planning. [Informe de la encuesta de opiniones sobre poblacion y planificacion familiar, dirigida a lideres politicos, gremiales, de comunicacion y centrales.]
  152. Report on the training of trainers in contraceptive technology and family planning program management.
  153. A report to the World Federation on the position relating to voluntary surgical contraception in some South Asian countries.
  154. Reproductive health: contraceptive methods. [Salud reproductiva: metodos anticonceptivos.]
  155. Reproductive mortality and oral contraceptives [letter]
  156. Reproductive mortality and oral contraceptives [letter]
  157. Research in biology of reproduction at the Instituto Mexicano del Seguro Social. IV. Contributions to family planning. [La investigacion de la biologia de la reproduccion en el Instituto Mexicano del Seguro Social. IV. Aportaciones a la planificacion familiar.]
  158. Research needs and priorities of family planning in China.
  159. Research on natural family planning in the Philippines.
  160. Research on the effects of hormonal contraceptives on lactation: current findings, methodological considerations and future priorities. [Recherches concernant les effets des contraceptifs hormonaux sur la lactation: etat actue des connaissances, considerations de methodologie et priorites.]
  161. Response to the article "A One-Sided View of Natural Family Planning" by Dr. Ramon Ruiz and the Hong Kong Marriage Advisory Council [letter]
  162. Results of a trial in Northumberland family planning clinics of Nicorette as an aid to stopping smoking.
  163. A retrospective study of IUD usage in a Malaysian family planning clinic.
  164. Review of FDA's assessment of the cancer risk presented by two contaminants in the Today contraceptive sponge.
  165. Review of some of the management aspects of the Indonesian Population and Family Planning Programme.
  166. Revised fact sheet on contraceptive sponge--"Today" for staff education and for use with the media.
  167. Risks of hormonal contraceptives. [Risiken der Ovulationshemmer.]
  168. Role of alkaline phosphatase in contraception--a review.
  169. The role of contraceptive substitution in the evaluation of family planning programs.
  170. Role of gestagens in contraception and the treatment of menstruation disorders in women. [Rola gestagenow w zapobieganiu ciazy i leczeniu zaburzen miesiaczkowania u kobiet.]
  171. The role of private sector in voluntary surgical contraception.
  172. The role of religion in family planning.
  173. The role of research and training in family planning programmes.
  174. Role of small organizations in referring sterilization clients and coordination with the whole system of population control by voluntary surgical contraception (VSC)
  175. The role of the clinician in natural family planning.
  176. The role of the midwife in family planning.

     

  177. The role of the midwife in permanent contraception.
  178. The role of the woman in family planning.
  179. Rupture of multiple hepatic adenoma and oral contraceptive use: a case report.
  180. Rural Survey of Family Planning, 1981. [Encuesta Rural de Planificacion Familiar, 1981.]
  181. Safety and efficacy of oral contraceptives.
  182. Safety of voluntary surgical contraception. Report of an expert committee.
  183. Satisfied users clubs: family planning acceptors as model agents of the program.
  184. Scheme for organizing reprints in population/family planning libraries.
  185. School, work and family planning: interim impacts in project redirection.
  186. Screening for chlamydial infections in women attending family planning clinics. Evaluation of presumptive indicators for therapy.
  187. A second look at natural family planning.
  188. Selected psychosocial characteristics of males: their relationship to contraceptive use and abortion.
  189. Selected tables on contraception from the Canberra Population Survey, 1979.
  190. Selection of contraception for the individual.
  191. Self-sufficiency: a necessity in family planning. [Autosuficiencia: una necesidad en la planificacion familiar.]
  192. Sequential study of plasma euglobin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
  193. Serum prostaglandin F levels during menstrual cycle in women using oral contraceptives.
  194. Serum zinc levels in pregnant women, under oral contraceptive therapy and in normal (ovulating) women.
  195. Service and psychosocial research in family planning: methodologic issues and constraints.
  196. Service and psychosocial research in the provision of family planning.
  197. Severe intrahepatic cholestasis due to the combined intake of oral contraceptives and triacetyloleandomycin.
  198. Sex and society in Islam: birth control before the nineteenth century.
  199. Sex hormones and related compounds, including oral contraceptives.
  200. Sexual behavior, contraceptive practice and reproductive health among the young unmarried population in Ibadan, Nigeria. Final report.
  201. Sexual experience and contraceptive practice of young women attending a youth advisory clinic.
  202. Sexuality, contraception and pregnancy in adolescence. [Sexualite, contraception et grossesse chez l'adolescente.]
  203. Sharing contraception: conditions for and strategies used by men and women to draw men into the family planning process [table]
  204. Sickle cell diseases and hormonal contraception.
  205. Side effects of hormonal contraceptives. [Zur Frage der Nebenwirkungen hormoneller Kontrazeptiva.]
  206. The Sierra Leone Planned Parenthood Association programme.
  207. The Singapore National Family Planning and Population Programme, 1966-1982.
  208. Social anxiety, sexual behavior, and contraceptive use.
  209. Social benefits of family planning.
  210. Social class and legal change: the birth control controversy.
  211. Social marketing of contraceptives project. [Projet de commercialisation sociale des contraceptifs.]
  212. Social research: issues and uses for voluntary surgical contraception services.
  213. A sociology of negative beliefs about the contraceptive pill in Egypt.
  214. Some aspects of China's family planning programme.
  215. Some aspects of the development of a postcoital contraception service in the West Midlands.
  216. Some basic age patterns of Indian women in a family planning programme.
  217. Some notes on issues requiring service--a psychosocial research in family planning: the Indonesian context.
  218. Some psychological problems in family planning work.
  219. A spatial analysis of factors relating to family planning in Thailand.
  220. Speech by Dr. Qian Xinzhong, Minister-in-charge of the State Family Planning Commission and Laureate of the United Nations Population Award, at the United Nations Population Award presentation ceremony (30 September 1983)
  221. Spontaneous abortion associated with Candida infection in the presence of an intrauterine contraceptive device.
  222. Sri Lanka Contraceptive Prevalence Survey report 1982.
  223. Sri Lanka contraceptive retail sales programme.
  224. Sri Lanka: population/family planning orientation booklet. First draft edition.
  225. Standard terms for voluntary surgical contraception.
  226. The state of the contraceptive art.
  227. Statistical approach of cervical and vaginal cytology during contraception (author's transl) [Approche statistique de la cytologie cervico-vaginale au cours de la contraception.]
  228. Status of voluntary surgical contraception in Asia.
  229. Status of voluntary surgical contraception in the French legal system.
  230. Steroidal contraception in the '80s: the role of current and new products.
  231. Steroidal contraceptive use and subsequent development of hyperprolactinemia.
  232. A stock adjustment model of contraceptive use in the Philippines.
  233. Strategies and schemes in family health, welfare and family planning in Africa.
  234. A strategy for family planning communication: findings of an evaluation study of family planning orientation training camps for opinion leaders in Maharashtra.
  235. Strategy for introduction of Norplant contraceptive subdermal implants.
  236. A structural analysis of acceptors and non-acceptors of family planning in remote rural areas (author's transl)
  237. A study of marital interactional roles: method effectiveness and satisfaction levels of couples who are using the Billings Ovulation Method of natural family planning in southern and western Puerto Rico.
  238. Study of nucleolar organizer in women with galactorrhea, or polycystic ovaries, or using oral contraceptive.
  239. A study of the endometrium after therapeutic abortion in relation to the contraceptive used following abortion. [Etude de l'endometre apres interruption volontaire de grossesse en relation avec la methode contraceptive utilisee dans le post-abortum.]
  240. A study on cost-effectiveness of family planning programme in 20 AFPH provinces.
  241. Study on packaging, logos, names, and colors of contraceptives in Haiti.
  242. Study on the presence of abnormal proteins in the serum of oral contraceptive users.
  243. Subnational estimation of contraceptive prevalence rates: an application of indirect estimation techniques to the 1979 Mexican Contraceptive Prevalence Survey. [Estimacion subnacional de tasas de prevalencia anticonceptiva: una aplicacion de tecnicas de estimacion sintetica en la Encuesta Mejicana de Prevalencia de Anticonceptivos de 1979.]
  244. Subnational estimation of contraceptive prevalence rates: an application of synthetic estimation techniques to the 1979 Mexican Contraceptive Prevalence Survey. State and regional estimation of the use of contraceptive methods. [Estimacion subnacional de tasas de prevalencia anticonceptiva: una aplicacion de technicas de estimacion sintetica en la encuesta mejicana de prevalencia de anticonceptivos de 1979. Estimaciones estatales y regionales de uso de metodos anticonceptivos, 1979.]
  245. Summary of the expert meeting on AID demographic and family planning data collection and analysis needs (september 21-22, 1983)
  246. Surgical contraception: the optimal method.
  247. A survey of attitudes concerning contraception and the resolution of teenage pregnancy.
  248. A survey of China's birth control among women of child-bearing age.
  249. Survey of information and opinions: population, family planning, sex education. [Encuesta de informacion y opiniones: poblacion, planificacion familiar, educacion sexual.]
  250. A survey of work done by the China family planning association.
  251. A survey on the use of contraceptives by adolescents. [Une enquete sur le recours des adolescentes a la contraception.]
  252. Systemic contraception at primary health care level and who should apply them.
  253. Systems effects on family planning innovativeness.
  254. T-post-partum, an intrauterine contraceptive for the immediate puerperium. [La T postparto un anticonceptivo intrauterino para el puerperio inmediato.]
  255. Take further steps to improve family planning work.
  256. Technical assistance in policy and planning for the Ministry of Interior Family Planning Support Project.
  257. Teenagers and contraception [letter]
  258. Teenagers and contraception [letter]
  259. Teenagers and contraception [letter]
  260. Teenagers and contraception [letter]
  261. The Tenth Asian Parasite Control/Family Planning Conference proceedings.
  262. Teratology study of intravaginally administered contraceptive jelly containing octoxynol-9 in rats.
  263. A test of the applicability of the health belief model to the arena of contraceptive decisionmaking.
  264. Textbook of contraceptive practice.
  265. Textbook of contraceptive practice. 2nd ed.
  266. A theological perspective on natural family planning.
  267. Third Expert Group Meeting on Methods of Measuring the Impact of Family Planning Programmes on Fertility.
  268. Third world family planning programs: measuring the costs.
  269. Three primaries method in pushing family planning ahead.
  270. Thrombotic thrombocytopenic purpura associated with oral contraceptives: a case report.
  271. Thyroid function in oral contraception: is there cyclic variation?
  272. Thyroid function in women: problems created by oral contraceptives, pregnancy and menopause (author's transl) [Fonction thyroidienne de la femme. Problemes poses par les contraceptifs oraux, la grossesse, la menopause.]
  273. Today vaginal contraceptive sponge: a technical review.
  274. Toxicity of a male contraceptive, gossypol, in mammalian cell cultures.
  275. Traditional midwifery and contraception.
  276. Training and manpower development in surgical contraception in Pakistan.
  277. Training effective field workers (a family planning training program)
  278. Training in information, education and communication for family planning: technical assistance to the Family Health Project of Senegal. Vol 1.
  279. Training in information, education and communication for family planning: technical assistance to the Family Health Project of Senegal. Vol. II. The training materials.
  280. Training of midwives in family planning in Nigeria.
  281. The training of workers for community based family planning and health projects [draft]
  282. Transfer of contraceptive production technology to developing countries.
  283. The treatment by the Egyptian press of the population and family planning problem: an analytical study in Jan-March, 1983.
  284. Trends in high risk births in Peninsular Malaysia in the decade following the implementation of the National Family Planning Program (1967 to 1977)
  285. Trends on mortality from carcinoma of the liver and the use of oral contraceptives.
  286. A trial of daily vitamin supplementation as a means of reducing oral contraceptive side effects and discontinuation in Sri Lanka.
  287. Trials and trends in vaginal contraception.
  288. Trip report: initial preparation for a contraceptive social marketing program in Jamaica, Kingston, Jamaica, February 27 - March 11, 1983.
  289. Triphasic oral contraceptives.
  290. Tubo-ovarian actinomycosis associated with the use of intrauterine contraceptive device (IUD) [Tubo-ovarial aktinomykose og intrauterin kontraception.]
  291. The U.S.-Mexico border: contraceptive use and maternal health care in perspective.
  292. Under-age contraception--whose responsibility? [editorial]
  293. Under-age girls and contraception [letter]
  294. Under-age girls and contraception: the parent's right to be informed.
  295. Unilobar small hepatic vein obstruction: possible role of progestogen given as oral contraceptive.
  296. Union catalog on population and family planning, Book 1. [Katalog induk bidang kependudukan keluarga berencana, Buku 1.]
  297. United States guidelines for counseling in voluntary surgical contraceptive programs.
  298. Unmet need for family planning services for health reasons.
  299. Unwanted pregnancy: a failure of contraceptive education.
  300. Update on contraceptives: what's safe? Effective? Convenient?
  301. Urinary estrogen and serum gonadotropin profiles in women ingesting oral contraceptive steroid formulations with variable estrogen content.
  302. Urinary steroid glucuronides in women taking oral contraceptives.
  303. Use and effectiveness of norethisterone enanthate for family planning in a rural area. [Uso y efectividad del enantato de noretisterona para la planificacion familiar en el area rural.]
  304. Use of combined oral contraceptive pills and cancer [letter]
  305. Use of combined oral contraceptive pills and cancer.
  306. The use of contraception for delaying and spacing births in Colombia, Costa Rica, and Korea.
  307. Use of contraceptive drugs in cardiac patients (editorial) [Uso de drogas contraceptivas en pacientes cardiacas.]
  308. Use of contraceptives in three south-east Asian countries.
  309. The use of family planning.
  310. Use of marketing research techniques in identification of problem areas in consumer perceptions and use of contraceptives: the contraceptive social marketing experience in El Salvador]
  311. Use of Ovidon, Rigevidon and Postinov for contraception. [Primenenie ovidona rigevidona i postinora stsel'iu kontratseptsii.]
  312. User's perspectives on family planning: some operational and research issues.
  313. Uterine perforation by a Copper 7 intrauterine contraceptive device with subsequent penetration of the appendix. Case report.
  314. Vaginal colonization of Escherichia coli and its relation to contraceptive methods.
  315. Vaginal contraception with gossypol: a clinical study.
  316. Vaginal contraception: mechanical or chemical? [La contraception vaginale: mecanique ou chimique?]
  317. Vaginal contraceptives merge old forms, new data.
  318. Vaginal mechanical contraceptive devices.
  319. Variability of pharmacokinetic parameters for contraceptive steroids.
  320. Vascular complications of oral contraception. In whom and how to prevent them? [Complications vasculaires de la contraception orale. Chez qui et comment les prevenir?]
  321. Vascular headaches and oral contraceptives.
  322. Vascular problems associated with the use of oral contraception. [Les problemes vasculaires lies a la contraception orale.]
  323. Vasectomy for contraception. [Vasektomie zur Empfangnisverhutung.]
  324. Vasospasm following transsphenoidal tumor removal associated with the arterial changes of oral contraception.
  325. Visit to Nepal. 9. Family planning in Nepal.
  326. Vitamin E (alpha tocopherol) in the management of menorrhagia associated with the use of intrauterine contraceptive devices (IUCD)
  327. VLI's contraceptive sponge: toxic shock warning urged by consumerist group.
  328. Voluntary sterilization-the leading method of family planning.
  329. The voluntary surgical contraception in Africa: realities and perspectives.
  330. Voluntary surgical contraception. Client referral systems.
  331. Voluntary surgical contraception. Keynote address. Inaugural ceremony, December 5, 1983.
  332. Weighing risks against benefits in contraceptive safety.
  333. Weight reduction, fertility and contraception.
  334. Welcome address (to 5th international conference on voluntary surgical contraception)
  335. What U.S. women think and do about contraception.
  336. When to recommend vaginal contraceptives.
  337. The Which? guide to birth control.
  338. Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors.
  339. Why do some couples have more children than they actually wanted? Hindrances to family planning.
  340. Women, fertility and contraception in rural Senegal. [Femmes, fecondite et contraception en milieu rural Senegalais.]
  341. Workshop on Oral Contraceptives and Breast Cancer.
  342. Young adult women's contraceptive decisions: a comparison of two predictive models of choice.
  343. Young persons' contraceptive clinic, 1975 to 1980: patterns of use.
  344. Zinc and copper concentrations in leucocytes and erythrocytes in healthy adults and the effect of oral contraceptives.
  345. ABH blood group antigens during pregnancy and in women on hormonal contraceptives.
  346. Actinomycosis of the female genital tract in wearers of intra-uterine contraceptive devices (author's transl) [Die Aktinomykose des weiblichen Genitaltraktes bei IUP-Tragerinnen.]
  347. Action of oral contraceptives on circulating immune complexes (author's transl) [Wirkung oraler Kontrazeptiva auf zirkulierende Immunkomplexe.]
  348. Scandinavian trial of an oral contraceptive containing 0.150 mg desogestrel and 0.030 mg ethinylestradiol.
  349. Sensitivity of the pituitary gland to LH-FSH releasing hormone in women after discontinuation of Ovidon, an estrogen-progesterone contraceptive agent. [Chuvstvitel'nost' gipofiza k LG-FSG-rilizing-gormonu u zhenshchin posle otmeny 'estrogen-progestagennago kontratsepnivnogo preparata ovidona.]
  350. Serotonin metabolism and depression in oral contraceptive users.
  351. Serum bile acids during biphasic contraceptive treatment with ethinyl estradiol and norgestrel.
  352. Serum lipoprotein and apolipoprotein changes during treatment with a contraceptive vaginal ring containing levonorgestrel and estradiol.
  353. Serum prolactin changes induced by the use of oral contraceptives and IUDs. [Modificazioni della prolattinemia indotte dall'impiego di contraccettivi orali e I.U.D.]
  354. Sex Education and contraceptive education in U.S. public high schools.
  355. Sex education and its association with teenage sexual activity, pregnancy and contraceptive use.
  356. Sex of offspring of women using oral contraceptives, rhythm, and other methods of birth control around the time of conception.
  357. An integrated service: 3. The role of the hospital family planning doctor.
  358. Intrauterine contraceptive devices for diabetics [letter]
  359. Intrauterine contraceptive devices in diabetic women.
  360. Reply to Nevius, Bennet, and Sobel [concerning oral contraceptives, smoking and heart disease]
  361. Results of a study to determine the effects of three oral contraceptives on serum lipoprotein levels.
  362. Adrenal function in hirsutism. II. Effect of an oral contraceptive.
  363. Alpha 2-antiplasmin and alpha 2-macroglobulin--the main inhibitors of fibrinolysis--during the menstrual cycle, pregnancy, delivery, and treatment with oral contraceptives.
  364. Alterations in clinical chemistry measures associated with oral contraceptive and estrogen use. The Lipid Research Clinics Program Prevalence Study.
  365. Anti-estrogenic effects of contraceptive progestins on the dynamics of gonadotropin release.
  366. Audit in family planning.
  367. Barrier-method contraceptives and pelvic inflammatory disease.
  368. Biosynthesis of platelet lipids in relation to aggregation in women using oral contraceptives.
  369. Body iron stores and patterns of bleeding after insertion of a levonorgestrel- or a copper-releasing intrauterine contraceptive device.
  370. Breast cancer in relation to patterns of oral contraceptive use.
  371. Carbohydrate metabolism studies in women using Brevicon, a low-estrogen type of oral contraceptive, for one year.
  372. Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality.
  373. Clinical and biochemical results during the treatment with Marvelon, a new oral contraceptive (author's transl) [Klinische und biochemische Resultate bei der Behandlung mit Marvelon--einem neuen steroidalen Ovulationshemmer.]
  374. Clinical evaluation of interval contraception by norethindrone acetate implant.
  375. Comparative effects of the oral contraceptive combinations 0.150 mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers.
  376. Contraception and diabetes.

     

  377. Contraception and fertility in the Netherlands.
  378. Contraception and pregnancy among young women in an urban Swedish population.
  379. Contraceptive failure in the United States: the impact of social, economic and demographic factors.
  380. Contraceptive intentions and subsequent behavior in rural Bangladesh.
  381. Contraceptive sterilization in four Latin American countries.
  382. Contraceptive use, pregnancy intentions and pregnancy outcomes among U.S. women.
  383. Copper intrauterine contraceptive device event rates following insertion 4 to 8 weeks postpartum.
  384. The decline of fertility in Costa Rica: literacy, modernization and family planning.
  385. The delivery and use of contraceptive services in rural Tunisia.
  386. The demographic impact of the contraceptive distribution project in Matlab, Bangladesh.
  387. The demographic impact of the Family Planning--Health Services Project in Matlab, Bangladesh.
  388. Diagnosis and treatment of intra-uterine contraceptive devices retained during pregnancy (author's transl) [Zur Diagnostik und Therapie okkulter Intrauterinpessare bei eingetretener Schwangerschaft.]
  389. Does progestogen reduction in oral contraception parallel reduced lipid metabolic effects?
  390. Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device.
  391. Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism.
  392. The effect of oral contraceptives on antiaggregatory prostacyclin and proaggregatory thromboxane A2 in humans.
  393. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
  394. Effects of desogestrel and levonorgestrel in low-dose oestrogen oral contraceptives on serum lipoproteins.
  395. Effects of oral contraception on liver function tests and serum proteins in women with active schistosomiasis.
  396. Effects of oral contraception on liver function tests and serum proteins in women with past viral hepatitis.
  397. Effects of oral contraceptives on lipoprotein triglyceride and cholesterol: relationships to estrogen and progestin potency.
  398. Effects of two oral contraceptive combinations, 0.125 mg desogestrel + 0.050 mg ethinylestradiol and 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol on the adrenal function of healthy female volunteers.
  399. Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 microgram norethisterone (NET) minipill.
  400. Epithelial ovarian cancer and combination oral contraceptives.
  401. An evaluation of the use-effectiveness of fertility awareness methods of family planning.
  402. Evidence against oral contraceptives as a cause of neural-tube defects.
  403. Extraction of pieces of an intrauterine contraceptive device. [Ekstrakhirane na skusan na chasti vutrematochen kontraseptiven pesar.]
  404. Factors affecting adolescents' use of family planning clinics.
  405. Factors affecting riboflavin requirements of oral contraceptive users and nonusers.
  406. Factors influencing the acceptance of family planning by Blacks in Salisbury, Zimbabwe.
  407. Family planning and abortion: have they affected fertility in Tennessee?
  408. Family planning communications and contraceptive use in Guatemala, El Salvador, and Panama.
  409. Fertility and family planning in Haiti.
  410. Fertility and family planning in the Irish Republic 1975.
  411. Fibrinolytic activity of uterine fluid in oral contraceptive users.
  412. Galactorrhea in oral contraceptive users.
  413. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives.
  414. Influence of contraceptive pill and menstrual cycle on serum lipids and high-density lipoprotein cholesterol concentrations.
  415. The law and sterilization or permanent contraception (author's transl) [Rechtliche Zulassigkeit der Sterilisation (dauernde Empfangnisverhutung)]
  416. Long-term intracervical contraception with a levonorgestrel device.
  417. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
  418. Management of amenorrhea due to contraceptive injectables by temporary IUD insertion.
  419. Measuring the unmet need for contraception to space and limit births.
  420. Metabolic clearance rates of luteinizing hormone in women during different phases of the menstrual cycle and while taking an oral contraceptive.
  421. Metabolic effects of the triphasic oral contraceptive Trigynon.
  422. Metabolic studies in gestational diabetic women during contraceptive treatment: effects on glucose tolerance and fatty acid composition of serum lipids.
  423. Metabolic studies in women with previous gestational diabetes during contraceptive treatment: effects on serum lipids and high density lipoproteins.
  424. Microbial presence in the uterine cavity as affected by varieties of intrauterine contraceptive devices.
  425. Modern, transitional, and traditional demographic and contraceptive patterns among Kenyan women.
  426. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. A preliminary report.
  427. Natural family planning: ovulation method after Billings (author's transl) [Naturliche Familienplanung: Die Ovulationsmethode nach Billings.]
  428. Need for family planning services among Anglo and Hispanic Women in U.S. counties bordering Mexico.
  429. Never-pregnant adolescents and family planning programs: contraception, continuation, and pregnancy risk.
  430. A new progestagen for oral contraception.
  431. Norethisterone, a major ingredient of contraceptive pills, is a suicide inhibitor of estrogen biosynthesis.
  432. The NORPLANT contraceptive method: a report on three years of use.
  433. Occurrence and histological structure of adenocarcinoma of the endocervix after long-term use of oral contraceptives (author's transl) [Vorkommen und histologische Struktur des Adenokarzinoms der Zervix-schleimhaut nach langjahriger Einnahme von Ovolationshemmern.]
  434. On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives.
  435. Oral contraception as a risk factor for preeclampsia.
  436. Oral contraceptives and blood coagulation: a critical review.
  437. Oral contraceptives and nonfatal vascular disease--recent experience.
  438. Oral contraceptives and pelvic inflammatory disease.
  439. Oral contraceptives and prolactinomas: a case-control study.
  440. Oral contraceptives and rheumatoid arthritis: further evidence for a preventive effect.
  441. Oral contraceptives and venous thromboembolism.
  442. Parental involvement: selling family planning clinics short.
  443. Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, ST-1435.
  444. Pituitary responsiveness to gonadotropin-releasing hormone (GnRH) and thyrotropin-releasing hormone (TRH) during different phases of the same cycle of oral contraceptive steroid therapy.
  445. Plasma high-density-lipoprotein cholesterol levels during long-term use of an oral contraceptive in Nigerian women.
  446. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
  447. Population and family planning in Mexico: progress and problems.
  448. Possible interactions of antihistamines and antibiotics with oral contraceptive effectiveness.
  449. Post family planning acceptance experience in the Caribbean: St. Kitts-Nevis and St. Vincent.
  450. A preliminary pharmacological trial of the monthly injectable contraceptive cycloprovera.
  451. The Prentif contraceptive cervical cap: acceptability aspects and their implications for future cap design.
  452. Prevalence of cervical neoplasia and infection in women using intrauterine contraceptive devices.
  453. Progestogen effects and their relationship to lipoprotein changes. A report from the Oral Contraception Study of the Royal College of General Practitioners.
  454. Progress in the contraceptive use of the LH-RH agonist buserelin by intermittent medication with withdrawal bleeding induced by a progestational agent. [Fortschritte in der kontrazpetiven Anwendung des LH-RH-Agonisten Buserelin: diskontinuierliche Medikation mit gestageninduzierter Abbruchblutung.]
  455. Protection against endometrial carcinoma by combination-product oral contraceptives.
  456. Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device.
  457. The Puerto Rico oral contraceptive study: an evaluation of the methodology and results of a feasibility study.
  458. Randomized comparative study of culdoscopy and minilaparotomy for surgical contraception in women.
  459. Randomized prospective studies on metabolic effects of oral contraceptives.
  460. A randomized, double-blind study of six combined oral contraceptives.
  461. A randomized, double-blind study of two combined and two progestogen-only oral contraceptives.
  462. Rating of conditions for family planning (author's transl) [Wertskalierungen von Familienplanungsbedingungen.]
  463. Role of abortion on demand and contraception in the reproductive process in a population. [Roliata na abortite po zhelanie i antikonseptsiiata v protsesa na vuzproizvodstvoto na naselenieto.]
  464. The role of mass media advertising campaigns in influencing attitudes towards contraception among 16-20 year olds.
  465. Routine liver function testing during long term administration of the oral contraceptive preparation 0.150 mg desogestrel plus 0.030 mg ethinylestradiol to healthy female volunteers in Scandinavia.
  466. Sexuality, fertility and contraception in disability.
  467. A simple and effective method for retrieving retracted threads of intrauterine contraceptive devices.
  468. Some metabolic effects of long-term use of the injectable contraceptive norethisterone oenanthate.
  469. Sources of family size attitudes and family planning knowledge among rural Turkish youth.
  470. Taking liberties with women: abortion, sterilization, and contraception.
  471. Teratology study of intravaginally administered nonoxynol-9-containing contraceptive cream in rats.
  472. A test of Luker's theory of contraceptive risk-taking.
  473. Thailand's family planning program: an Asian success story.
  474. The transition in Korean family planning behavior, 1935-1976: a retrospective cohort analysis.
  475. Trends in the use of oral contraceptives among Dutch young women 1975-1981.
  476. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination.
  477. Ultrastructure of cervical mucus and sperm penetration during use of a triphasic oral contraceptive.
  478. Venous and arterial thromboembolic disease in women using oral contraceptives.
  479. Voluntary childlessness and contraception: problems and practices.
  480. Women's acceptability of the condom and diaphragm in Shatby Family Planning Clinic in Alexandria.
  481. IUDs: an appropriate contraceptive for many women./DIU: un anticonceptivo apropiado para muchas mujeres.
  482. Community-based health and family planning./La sante et le planning familial a base communautaire./Salud y planificacion familiar basadas en la comunidad./Saude e planejamento familiar na comunidade.
  483. Oral contraceptives in the 1980s./Les contraceptifs oraux pendant les annees 80./Anticonceptivos orales en el de decenio 1980./Os anticoncepcionais orais na decada de 1980.
  484. 1980 Lagos contraception and breast-feeding study. Final report.
  485. 25 years of hormonal contraception. [A hormonalis anticonceptio 25 eve.]
  486. Abortion and contraception in the Korean fertility transition.
  487. Abortion and contraception in the Netherlands.
  488. Abortion and contraception seen through the pages of "Population" (1970-1981) [Avortement et contraception vus a travers "Population" (1970-1981)]
  489. Abortion and contraception.
  490. Abortion, birth control and family planning 1981.
  491. Absence of correlation between oral contraceptive usage and ischemic heart disease.
  492. Acceptability of low-dose oral contraceptives: results of a randomized Swedish multicenter study comparing a triphasic (Trionetta) and a fixed-dose combination (Neovletta)
  493. Acceptability of medroxyprogesterone acetate among medical and paramedical personnel in family planning. [Aceptabilidad del acetato de medroxiprogesterona entre personal medico y paramedico en planificacion familiar.]
  494. Acceptance and prevalence of family planning in the Southern Tagalog and North Mindanao regions.
  495. Acceptance of family planning in Greater Bombay.
  496. Acceptance of family planning in rural Haryana.
  497. Acceptance of family planning practice among rural women clientele.
  498. Acceptance of hormonal contraception versus intrauterine devices (IUD). Comparison of 515 women using hormonal contraception with 198 women using IUDs. [Akzeptanz hormonaler Kontrazeption versus Intra-Uterin-Pessar (IUD). Vergleich von 515 Frauen unter hormonaler Kontrazeption mit 198 Frauen mit IUD.]
  499. Actinomycosis of the genitals and the use of intrauterine contraceptive devices. [Promienica narzadow rodnych a stosowanie wewnatrzmacicznych wkladek antykoncepcyjnych.]
  500. Acute digestive complications of oral contraceptives. [Les accidents digestifs aigus des contraceptifs oraux.]

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.